A composition with the function of improving uric acid metabolism, preparation method and application thereof
By combining the application of vitamin C, sophora extract, green tea extract and turmeric extract, the problems of existing adverse reactions of drugs for treating hyperuricemia and complex Chinese patent medicine formulas have been solved, and safe and effective improvement of uric acid metabolism and gout are achieved. Relieve effect.
Patent Information
- Application Number
- CN202211095192.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-09-05
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2042-09-05
AI Technical Summary
The existing drugs for treating hyperuricemia have adverse reactions and complex formulations of Chinese patent medicines and difficult quality control. They lack safe and non-toxic medicinal and food homologous raw materials to improve uric acid metabolism.
Using medicinal and food homologous and health products available raw materials, vitamin C, sophora extract, green tea extract and turmeric extract are combined through modern preparation technology to prepare compositions with improved uric acid metabolism function to reduce uric acid and relieve uric acid. gout.
This composition significantly improves uric acid metabolism, assists in lowering uric acid, and relieves gout. Since the raw materials are derived from medicinal and food homologous and health products, it is safe and non-toxic side effects, which is of great significance.
Smart Images

Figure BDA0003832481140000041 
Figure BDA0003832481140000051 
Figure BDA0003832481140000071
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of medicine and food processing, and specifically relates to a composition having the function of improving uric acid metabolism, a preparation method and application thereof. Background Art
[0002] Uric acid is a heterocyclic compound containing carbon, nitrogen, oxygen, and hydrogen. It is the end product formed after purine metabolism in the liver, muscles, and intestines. It is mainly formed after the decomposition of adenylic acid and guanine. Xanthine and hypoxanthine generated from purine are converted into uric acid through the enzymatic reaction of xanthine oxidase (XO). Hyperuricemia (HUA) is a metabolic disease caused by abnormal purine metabolism, which leads to excessive production and / or reduced excretion of uric acid, resulting in blood uric acid exceeding the normal range. Long-term hyperuricemia can cause urate crystal deposition in joints and surrounding soft tissues, leading to recurrent acute joint and soft tissue inflammation, tophi deposition, chronic arthritis, and joint damage. Hyperuricemia can also affect the kidneys, causing chronic interstitial nephritis and urate stone formation.
[0003] In recent years, with the improvement of living standards and changes in people's living structure, the prevalence of hyperuricemia has gradually increased, and the age of patients has shown a clear trend of younger age. At present, the main Western medicines for the clinical treatment of hyperuricemia are allopurinol, colchicine, febuxostat, benzbromarone, etc. Although they can effectively reduce uric acid, they are also prone to cause adverse reactions such as diarrhea, abdominal pain, rash, liver damage, and even benzbromarone has the risk of liver damage.
[0004] In addition to clinical prescriptions, Chinese patent medicines are also recommended for the prevention and treatment of hyperuricemia gout, such as Tongfeng Ding Tablets, Tongfeng Shu Tablets, Fufang Shenjin Capsules, Simiao Pills, etc. Chinese medicines used to lower uric acid mainly regulate the liver, spleen, stomach, kidneys, bladder and other internal organs. Sweet and warm, flat tonic and diuretic and dampness-infiltrating drugs, or bitter and cold, heat-clearing and laxative drugs are widely used. Their indications are mostly joint swelling and pain caused by gout. However, Chinese patent medicines also have many shortcomings in the prevention and treatment of uric acid lowering, such as the complex formula of Chinese medicine, the large number of raw materials, and the difficulty in controlling the quality of Chinese medicinal materials. Some Chinese medicinal materials also contain some drug ingredients that are harmful to the body. Long-term use will lead to enrichment, thereby damaging health. At the same time, pharmaceutical products need to be used under the guidance of clinical doctors or pharmacists, and there are few related medicine and food products.
[0005] Sophora japonica seeds are cold in nature, sweet and flat in taste, and have the effects of reducing capillary permeability, anti-oxidation, anti-inflammatory, anti-viral and inhibiting aldose reductase.
[0006] Green tea has multiple pharmacological effects, including anti-oxidation, anti-aging, lipid-regulating, blood sugar-lowering, anti-atherosclerosis, anti-cancer, bactericidal, anti-inflammatory, antiviral, and treatment of neurodegenerative diseases.
[0007] Turmeric mainly contains ingredients such as curcumin and volatile oils, which play a role in anti-inflammatory, antiviral, lipid-lowering and anti-tumor effects.
[0008] Vitamin C promotes the excretion of uric acid. A certain dose of vitamin C can achieve a good effect in lowering uric acid and preventing gout.
[0009] In view of this, the present invention seeks raw materials that can improve uric acid metabolism and have no toxic side effects from raw materials that are both medicinal and edible and available for health care products, and provides a composition with the function of improving uric acid metabolism through modern preparation technology, which is of great significance for improving uric acid metabolism, preventing hyperuricemia and alleviating gout. Summary of the invention
[0010] The purpose of the present invention is to overcome the deficiencies in previous studies and provide a composition with the function of improving uric acid metabolism. The composition is formulated with raw materials that are both medicinal and edible and can be used as health products, and vitamin C is used in combination with sophora japonica seed extract, green tea extract, and turmeric extract to achieve synergistic effects, and has the effects of significantly improving uric acid metabolism, assisting in lowering uric acid, and relieving gout.
[0011] To achieve the above purpose, the technical solution adopted by the present invention is as follows:
[0012] Firstly, the present invention provides a composition with the function of improving uric acid metabolism, comprising the components of: Sophora japonica flower extract and vitamin C.
[0013] Preferably, in the composition, the weight ratio of Sophora japonica extract to vitamin C is (5-30):(1-6), more preferably (10-30):(1-3), and even more preferably 10:3.
[0014] Preferably, the composition further comprises the following components: green tea extract and turmeric extract.
[0015] Further preferably, in the composition, the weight ratio of the Sophora japonica extract, the green tea extract, the turmeric extract and the vitamin C is (5-30):(1-8):(1-9):(1-6).
[0016] More preferably, the weight ratio of Sophora japonica extract, green tea extract, turmeric extract and vitamin C is (10-30):(2-8):(3-9):(1-3).
[0017] Most preferably, the weight ratio of Sophora japonica extract, green tea extract, turmeric extract and vitamin C is 10:2:3:3.
[0018] Secondly, the present invention provides a method for preparing the above composition, comprising the following steps:
[0019] Sophora japonica seed is mixed with 6-12 times of water, boiled and extracted 2-3 times, each time for 1-2 hours, and the extract is hydrolyzed and dried to obtain Sophora japonica seed extract; green tea is mixed with 6-12 times of water, extracted 2-3 times at 70-100° C. for 0.5-1.5 hours each time, filtered, concentrated and dried to obtain green tea extract; turmeric is mixed with 8-15 times of 60%-80% ethanol-water solution, extracted for 4-6 hours, filtered, concentrated at 50-70° C. to a solid content of ≥60%, 75-95% ethanol in an amount of 20-40% by volume of the medicinal material is added for alcohol precipitation, and the lower precipitate is collected and dried to obtain turmeric extract; Sophora japonica seed extract, green tea extract, turmeric extract and vitamin C are mixed to obtain the above-mentioned composition.
[0020] Preferably, the sophora japonica buds are dried flower buds of the leguminous plant Sophora japonica.
[0021] Preferably, the turmeric is the dried rhizome of the turmeric plant of the Zingiberaceae family.
[0022] Furthermore, the present invention provides the use of the above composition in preparing a product having the function of regulating uric acid metabolism.
[0023] Finally, the present invention provides a product having the function of regulating uric acid metabolism, including the above-mentioned composition having the function of regulating uric acid metabolism of the present invention.
[0024] Preferably, the dosage forms of the product include soft capsules, powders, hard capsules, tablets, teas, oral liquids, wine preparations, granules, candies, effervescent tablets, and pills.
[0025] Further preferably, the tablets of the product further include components: at least one of lactose, edible corn starch, cross-linked polyvinylpyrrolidone, sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, magnesium stearate, and film coating premix.
[0026] More preferably, the tablets of the product comprise the following components by weight: 50-300 parts of Sophora japonica seed extract, 10-80 parts of green tea extract, 10-90 parts of turmeric extract, 10-60 parts of vitamin C, 50-100 parts of lactose, 20-40 parts of edible corn starch, 1-15 parts of cross-linked polyvinylpyrrolidone, 0.5-2 parts of sodium carboxymethyl cellulose, 5-20 parts of low-substituted hydroxypropyl cellulose, 1-3 parts of magnesium stearate, and 1-5 parts of film coating premix.
[0027] Most preferably, the tablets of the product comprise the following components by weight: 100 parts of Sophora japonica extract, 20 parts of green tea extract, 30 parts of turmeric extract, 30 parts of vitamin C, 94 parts of lactose, 33 parts of edible corn starch, 10 parts of cross-linked polyvinylpyrrolidone, 1 part of sodium carboxymethyl cellulose, 10 parts of low-substituted hydroxypropyl cellulose, 2 parts of magnesium stearate, and 3 parts of film coating premix.
[0028] Preferably, the product is a dietary supplement, a health food or a medicine.
[0029] Compared with the prior art, the present invention has the following beneficial effects:
[0030] 1. The combined use of vitamin C and Sophora japonica extract, green tea extract and turmeric extract can achieve a synergistic effect.
[0031] 2. All raw materials are derived from medicinal and edible materials and raw materials that can be used in health care products. They are safe and have no toxic side effects.
[0032] 3. Vitamin C can enhance the uric acid-lowering effect of Sophora japonica extract, green tea extract, and turmeric extract, and has the effects of significantly improving uric acid metabolism, assisting in lowering uric acid, and relieving gout. It is of great significance for improving uric acid metabolism, preventing hyperuricemia, and relieving gout. DETAILED DESCRIPTION
[0033] The following non-limiting examples can enable those skilled in the art to more fully understand the present invention, but do not limit the present invention in any way. The following content is merely an exemplary description of the scope of protection claimed in this application, and those skilled in the art can make various changes and modifications to the invention of this application based on the disclosed content, which should also fall within the scope of protection claimed in this application.
[0034] The present invention is further described below by way of specific examples. The various chemical reagents used in the examples of the present invention are obtained through conventional commercial channels unless otherwise specified. The contents described below are all by mass.
[0035] The components of each embodiment formula are shown in Table 1, and the components of each comparative example formula are shown in Table 2:
[0036] Examples 1-7
[0037] Preparation of Sophora japonica extract: Sophora japonica extract was mixed with 10 times the amount of water, boiled and extracted twice, each time for 1.5 hours, and the extract was filtered, concentrated by rotary evaporation, and dried to prepare Sophora japonica extract;
[0038] Green tea extract: Mix green tea with 10 times the amount of water, extract twice at 90°C for 1 hour each time, filter, concentrate by rotary evaporation, and dry to prepare green tea extract;
[0039] Turmeric extract: Turmeric is mixed with 12 times the amount of 70% ethanol-water solution, stirred and extracted at room temperature for 5 hours, filtered, concentrated at 60°C to a solid content of more than 60%, and 80% ethanol in an amount of 40% by volume of the medicinal material is added for alcohol precipitation. The lower precipitate is collected and dried to prepare the turmeric extract;
[0040] Sophora japonica extract, green tea extract, turmeric extract and vitamin C are mixed according to the weight parts in Table 1 to obtain a composition with the function of improving uric acid metabolism.
[0041] Table 1
[0042]
[0043]
[0044] Comparative Examples 1-14
[0045] Sophora japonica extract, green tea extract, turmeric extract and vitamin C are mixed according to weight parts shown in Table 2 to obtain a composition with the function of improving uric acid metabolism.
[0046] Table 2
[0047] Comparative Example composition Weight sample Comparative Example 1 Sophora japonica extract 10 Sample 8 Comparative Example 2 Green Tea Extract 2 Sample 9 Comparative Example 3 Turmeric Extract 3 Sample 10 Comparative Example 4 Vitamin C 3 Sample 11 Comparative Example 5 Sophora japonica extract: Green tea extract 10:2 Sample 12 Comparative Example 6 Sophora japonica extract: Turmeric extract 10:3 Sample 13 Comparative Example 7 Green Tea Extract: Turmeric Extract 2:3 Sample 14 Comparative Example 8 Sophora japonica extract: Vitamin C 10:3 Sample 15 Comparative Example 9 Green Tea Extract: Vitamin C 2:3 Sample 16 Comparative Example 10 Turmeric Extract: Vitamin C 3:3 Sample 17 Comparative Example 11 Sophora japonica extract: Green tea extract: Turmeric extract 10:2:3 Sample 18 Comparative Example 12 Sophora japonica extract: Green tea extract: Vitamin C 10:2:3 Sample 19 Comparative Example 13 Sophora japonica extract: Turmeric extract: Vitamin C 10:3:3 Sample 20 Comparative Example 14 Green Tea Extract: Turmeric Extract: Vitamin C 2:3:3 Sample 21
[0048] Results
[0049] Experimental Example 1: Functional activity test of samples on rat model of hyperuricemia and gout
[0050] 1. Experimental materials and instruments
[0051] 1.1 Drugs and reagents: D-fructose, vitamin C, Sophora japonica extract, green tea extract, turmeric extract, benzbromarone tablets (positive control for lowering uric acid), colchicine tablets (positive control for anti-gout), and uric acid detection kit.
[0052] 1.2 Instruments: water bath, vacuum drying oven, sunrise microplate reader, low-speed centrifuge.
[0053] 1.3 Experimental animals: SPF-grade SD rats, weighing 200±20 g, male, provided by Beijing Sibeifu Experimental Animal Technology Co., Ltd., certificate number: SCXK(Beijing)2019-0010.
[0054] 2. Experimental Methods
[0055] 2.1 Grouping and Methods:
[0056] The SD rats were stratified by body weight using the random number table method, and each layer was divided into a normal group (12 rats), a fructose modeling group (12 rats), a positive drug control group (12 rats each in the uric acid lowering benzbromarone group and the anti-gout colchicine group), and 12 rats each in the sample 1-7 groups. The normal group was given drinking water and gavage once a day according to body weight; the fructose modeling group, the benzbromarone group, the colchicine group, and the sample 1-7 groups were given 10% fructose water for modeling, and the drugs were gavaged once a day according to body weight, with a gavage volume of 10 ml / kg. The rats' food and water intake were recorded daily, and their body weight was weighed every 10 days. The tail was cut and blood was collected the next day after weighing. The results of changes in serum uric acid (UA) levels are shown in Table 3.
[0057] When the blood uric acid level of the fructose modeling group was significantly higher than that of the normal group (P < 0.05), and the blood uric acid level of the test drug and benzbromarone groups was significantly lower than that of the model group, 25 mg / ml sodium urate crystals were injected into the ankle joints of the other groups except the normal group to induce gouty arthritis model in rats. The normal group was free to drink water, and the ankle joints were injected with an equal dose of normal saline.
[0058] 2.2 Detection indicators:
[0059] During the experiment, the tail was cut and blood was collected every 10 days to detect serum uric acid (SUA) levels and the results were recorded. The results are shown in Table 1. When the blood uric acid level of the fructose modeling group was significantly higher than that of the normal group (P < 0.05), and the blood uric acid levels of the test drug group and the benzbromarone group were significantly lower than those of the model group, an acute gouty arthritis model was established, and the joint swelling levels of the rats were measured at 4h, 8h, 12h, and 24h. The results are shown in Table 4.
[0060] 2.3 Experimental Results
[0061] 2.3.1 Changes in serum uric acid (UA) levels
[0062] Table 3
[0063]
[0064]
[0065] Note: n=12, Unit: μmol / L. Compared with the normal group: * P<0.05, ** P<0.01; compared with the model group: ## P<0.01.
[0066] As can be seen from Table 3, on the 30th day of the experiment, compared with the normal group, the serum uric acid level of the rats in the model group was significantly increased (P<0.01); compared with the model group, the serum uric acid level of the rats in the positive drug benzbromarone group was significantly decreased (P<0.01), and the serum uric acid level of the rats in the sample 1-7 groups was significantly decreased (P<0.01); this shows that samples 1-7 have a significant effect on lowering uric acid, among which sample 3 has the best effect; from the results of sample groups 1, 2 and 7, it can be seen that when the dosage of other raw materials is the same, within a certain range of vitamin C dosage, the uric acid value of the low-dose vitamin C group on the 30th day is lower than that of the high-dose vitamin C group.
[0067] 2.3.2 Ankle joint swelling level
[0068] Table 4
[0069]
[0070]
[0071] Note: n=12, Unit: %. Compared with the normal group: * P<0.05, ** P<0.01; compared with the model group: # P<0.05, ## P<0.01.
[0072] As shown in Table 4, 4 hours after the injection of sodium urate suspension into the ankle joint, the joint swelling of the rats in the model group was significantly increased compared with the normal group (P<0.01), and the colchicine group showed a decreasing trend compared with the model group, but there was no significant difference; 8 hours after the injection, the joint swelling of the rats in the model group was significantly increased compared with the normal group (P<0.01), and the colchicine group showed a decreasing trend compared with the model group, but there was no significant difference; 12 hours after the injection, the joint swelling of the rats in the model group was significantly increased compared with the normal group (P<0.01), and the colchicine group showed a significant difference compared with the model group (P <0.01); there were no significant differences in the other groups; 24 hours after injection, compared with the normal group, the joint swelling of the model group rats was significantly increased (P<0.01), compared with the model group, the joint swelling of the colchicine group and sample 1-7 groups was significantly reduced (P<0.05 or P<0.01). From the results of sample group 1, sample group 2 and sample group 7, it can be seen that when the dosage of other raw materials is the same, there is no significant difference between the anti-gout effects of high-dose vitamin C and low-dose vitamin C, and the swelling of the high-dose vitamin C group is slightly higher than that of the low-dose group. Therefore, the low concentration of vitamin C in the composition has a better anti-gout effect.
[0073] Experimental Example 2 In vitro screening of anti-xanthine oxidase activity
[0074] 1. Experimental materials and instruments
[0075] 1.1 Samples and reagents: vitamin C, Sophora japonica extract, green tea extract, turmeric extract, xanthine, xanthine oxidase (XOD), potassium dihydrogen phosphate, sodium hydroxide.
[0076] 1.2 Instruments: ultrasonic cleaner, water purifier, UV-VIS spectrophotometer, electric constant temperature water bath, analytical balance.
[0077] 2. Test methods
[0078] 2.1 Configuration of main reagents
[0079] Phosphate buffer solution: prepare 0.2mol / L potassium dihydrogen phosphate solution and 0.2mol / L sodium hydroxide solution, mix 250ml potassium dihydrogen phosphate solution with 205mL sodium hydroxide solution, and make up to 1000mL. Preparation of xanthine solution: weigh 15mg xanthine, add 1mL ammonia water, warm water bath until completely dissolved, make up to volume with phosphate buffer, prepare 1mmol / L xanthine solution, dilute 10 times before use, that is, 0.1mmol / L xanthine application solution. Preparation of xanthine oxidase solution: take 500U xanthine oxidase and dissolve it in a 10mL volumetric flask and make up to 50U / mL, prepare and use it now. Preparation of sample solution: accurately weigh 5mg of sample and dissolve it in 10mL phosphate buffer solution to obtain 0.5mg / mL sample solution.
[0080] 2.2 Determination of the inhibitory ability of samples on xanthine oxidase
[0081] With xanthine as the reaction substrate, the uric acid generated by the reaction has an obvious characteristic absorption peak at 290nm, and the amount of uric acid generated reflects the activity of xanthine oxidase. The amount of substances added in each group of the experiment is shown in Table 5.
[0082] Table 5
[0083]
[0084] Phosphate buffer, the test substance of different raw material combinations, xanthine oxidase (50U / mL) and xanthine solution (0.1mmol / L) were added to a 5mL test tube in sequence, and then reacted at 25°C for 30min, and the OD value of each group was measured at 290nm. The final concentration of the samples was 100μg / mL. The inhibition rate of xanthine oxidase by samples of different raw material combinations was calculated according to the following formula.
[0085]
[0086] In the formula, A i is the inhibition rate of the sample experimental group; Aj is the inhibition rate of the sample blank group; A0 is the inhibition rate of the control experimental group; A1 is the inhibition rate of the control blank group.
[0087] 2.3 Experimental Results
[0088] Table 6 shows the results of the xanthine oxidase inhibition activity of the samples. Vitamin C alone has a very weak inhibitory effect on XOD, but the combined use of vitamin C and the other raw materials of the present invention has a significantly higher XOD inhibition rate than vitamin C (P<0.01); the samples without vitamin C have an inhibition rate of less than 50% on XOD, and the combined use of vitamin C and the extract of the present invention can make the inhibition rate of each sample on XOD exceed 50%. Among them, sample 3 has the strongest inhibitory effect on XOD, and there is a statistical difference compared with other samples (P<0.05). It shows that the combined use of vitamin C and the three extracts can significantly enhance the inhibitory effect of the composition on XOD.
[0089] Table 6
[0090] Group Inhibition rate (%) Sample 3 <![CDATA[89.2 # ]]> Sample 7 82.6 Sample 8 <![CDATA[36.4 *# ]]> Sample 9 <![CDATA[28.1 *# ]]> Sample 10 <![CDATA[33.6 *# ]]> Sample 11 <![CDATA[0.9 * ]]> Sample 12 <![CDATA[40.2 *# ]]> Sample 13 <![CDATA[38.4 *# <!-- 7 -->]]> Sample 14 <![CDATA[37.5 *# ]]> Sample 15 <![CDATA[69.8 *# ]]> Sample 16 <![CDATA[62.3 *# ]]> Sample 17 <![CDATA[65.0 *# ]]> Sample 18 <![CDATA[46.5 *# ]]> Sample 19 <![CDATA[76.3 *# ]]> Sample 20 <![CDATA[72.4 *# ]]> Sample 21 <![CDATA[73.6 *# ]]>
[0091] Note: Compared with sample 3: *P<0.05, compared with sample 11: #P<0.01
[0092] Experimental Example 3 Preparation of product tablets with the function of regulating uric acid metabolism
[0093] A raw material formula (by weight) of a product tablet with the function of regulating uric acid metabolism:
[0094] 100 parts of Sophora japonica extract, 20 parts of green tea extract, 30 parts of turmeric extract, 30 parts of vitamin C, 94 parts of lactose, 33 parts of edible corn starch, 10 parts of cross-linked polyvinylpyrrolidone, 1 part of sodium carboxymethyl cellulose, 10 parts of low-substituted hydroxypropyl cellulose, 2 parts of magnesium stearate, and 3 parts of film coating premix.
[0095] A method for preparing a product tablet having the function of regulating uric acid metabolism comprises the following steps:
[0096] (1) Preparation of adhesive: Preparation of sodium carboxymethylcellulose solution: Weigh the required amount of hot purified water and pour it into a stirring tank, place sodium carboxymethylcellulose in the stirring tank to prepare a sodium carboxymethylcellulose solution with a concentration of 0.8%, and set aside;
[0097] (2) One-step granulation: Sophora japonica extract, turmeric extract, green tea extract, edible corn starch, part of cross-linked polyvinylpyrrolidone, and lactose are pumped into a wet mixing granulator through vacuum feeding. After dry mixing for 300 seconds, the mixture is passed through a 4*4mm sieve, and the boiling granulator is turned on. All the materials are transferred to the fluidized bed through vacuum suction. When the material temperature reaches 50°C, spray granulation is started, and the prepared 0.8% sodium carboxymethyl cellulose solution is used for spray granulation; the spraying speed and the boiling of the material are controlled to keep them in the best state. When the slurry is sprayed to a certain amount, the material is taken from the sampling port for observation. Drying can be started after the particle size, properties, and quality meet the process requirements;
[0098] (3) Drying: When the moisture content of the pellets is ≤2%, the pellets are discharged and pulled out of the container;
[0099] (4) Granulation: Pass the granules in the container through a 2.0 mm sieve and set aside;
[0100] (5) Total mixing: the granules prepared by one-step granulation and the remaining cross-linked polyvinylpyrrolidone, low-substituted hydroxypropyl cellulose, and vitamin C are placed in a single-arm fixed hopper mixer and mixed for 25 min. Magnesium stearate is then added and mixed for 5 min. After checking that the mixture is evenly mixed, the mixture is discharged for use.
[0101] (6) Tablet pressing: Use Fite 102i tablet press, theoretical tablet weight: 850 mg / tablet, hardness 10±2 kg / cm 2 , friability ≤ 0.5%. During tableting, check the average tablet weight, tablet weight control range, and appearance according to the record requirements to ensure that the tablet weight range is within 850mg×(1±4.5%), that is, each tablet is 811.75-888.25mg;
[0102] (7) Coating: Use film coating premix for coating, coating weight gain: 1%, coating slurry solid content 10%, tablet weight after coating 858.5 mg / tablet.
[0103] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.
Claims
1. A composition having the function of improving uric acid metabolism, characterized in that: The composition is composed of the following components in parts by weight: Sophora japonica extract, green tea extract, turmeric extract and vitamin C in a weight ratio of (10-30):(2-8):(3-9):(1-3).
2. The composition according to claim 1, characterized in that The weight ratio of the Sophora japonica seed extract, the green tea extract, the turmeric extract and the vitamin C is 10:2:3:
3.
3. The method for preparing the composition according to any one of claims 1 to 2, characterized in that: The following steps are involved: Mix the formulated amount of Sophora japonica seeds with 6-12 times the amount of water, boil and extract for 2-3 times, each time for 1-2 hours, and prepare Sophora japonica seeds extract through hydrolysis and drying process; The green tea in the formula amount is mixed with 6-12 times the amount of water, extracted 2-3 times at 70-100° C., each time for 0.5-1.5 hours, filtered, concentrated, and dried to prepare the green tea extract; The formulated amount of turmeric is mixed with 8-15 times the amount of 60%-80% ethanol, extracted for 4-6 hours, filtered, concentrated at 50-70°C to a solid content of ≥60%, and 75-95% ethanol in an amount of 20-40% by volume of the medicinal material is added for alcohol precipitation, and the lower precipitate is collected and dried to obtain a turmeric extract; The composition is obtained by mixing the sophora japonica extract, green tea extract, turmeric extract and vitamin C.
4. Use of the composition according to any one of claims 1 to 2 in the preparation of a product having the function of regulating uric acid metabolism.
5. A product having the function of regulating uric acid metabolism, characterized in that: A composition having the function of regulating uric acid metabolism comprising the composition according to any one of claims 1 to 2.
6. The product having the function of regulating uric acid metabolism according to claim 5, characterized in that: The dosage forms of the product include soft capsules, powders, hard capsules, tablets, tea, oral liquid, wine, granules, candies, effervescent tablets, and pills.
7. The product having the function of regulating uric acid metabolism according to claim 6, characterized in that: The tablets of the product further include components: at least one of lactose, edible corn starch, cross-linked polyvinylpyrrolidone, sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose, magnesium stearate, and film coating premix.
8. A product having the function of regulating uric acid metabolism, characterized in that: The tablets of the product comprise the following components by weight: 50-300 parts of Sophora japonica extract, 10-80 parts of green tea extract, 10-90 parts of turmeric extract, 10-60 parts of vitamin C, 50-100 parts of lactose, 20-40 parts of edible corn starch, 1-15 parts of cross-linked polyvinylpyrrolidone, 0.5-2 parts of sodium carboxymethyl cellulose, 5-20 parts of low-substituted hydroxypropyl cellulose, 1-3 parts of magnesium stearate and 1-5 parts of film coating premix.
